Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;13(8):1432-9.
doi: 10.2174/1871527313666141023141545.

Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus

Gohar Mushtaq, Nigel H Greig, Jalaluddin A Khan, Mohammad A Kamal  1
Affiliations
Review

Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus

Gohar Mushtaq et al. CNS Neurol Disord Drug Targets. 2014.

Abstract

Both Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM) share the presence of systemic and neuro-inflammation, enhanced production and accumulation of β -amyloid peptide and abnormal levels of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Altered levels of AChE and BuChE both in AD as well as in T2DM imply that those two enzymes may be playing a pivotal role in the pathogenesis of the two disorders. AD and T2DM are both characterized by elevated levels of AChE and BuChE in the plasma. On the other hand, in AD the brain levels of AChE go down while those of BuChE go up, resulting in deregulation in balance between AChE and BuChE. This imbalance and change in the AChE/BuChE ratio causes cholinergic deficit in the brain, i.e. deficiency in the brain neurotransmitter acetylcholine. With better understanding of the inter-relationship of AChE and BuChE levels in normality as well as abnormality, AD and T2DM can be effectively treated. Thus, general cholinesterase inhibitors that inhibit both AChE and BuChE as well as highly selective BuChE inhibitors may have potential therapeutic benefits in the treatment of AD and other related dementias.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

Figures

Fig. 1
Fig. 1
Cholinesterase inhibitors in Alzheimer’s disease (AD) and Type 2 Diabetes mellitus (T2DM).
See this image and copyright information in PMC

References

    1. Kaplay SS. Acetylcholinesterase and butyrylcholinesterase of developing human brain. Biol Neonate. 1976;28:65–73. - PubMed
    1. Jope RS, Walter-Ryan WG, Alarcon RD, Lally KM. Cholinergic processes in blood samples from patients with major psychiatric disorders. Biol Psychiatry. 1985;20:1258–66. - PubMed
    1. Silver A. The biology of cholinesterases. Elsevier/Agricultural Research Council Institute; New York: 1974. pp. 426–47.
    1. Li B, Stribley JA, Ticu A, et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem. 2000;75(3):1320–31. - PubMed
    1. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;4(2):131–8. - PubMed

Publication types

MeSH terms

LinkOut - more resources